KONVERSIONNAYa I NEOAD\"YuVANTNAYa TERAPIYa PRI METASTAZAKh KOLOREKTAL'NOGO RAKA V PEChEN'


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Colorectal cancer (CRC) is the third largest of cancer mortality in the world. Approximately 25 % of patients have metastases to distant organs at the time of diagnosis (synchronous metastasis), and about 50 % of patients suffer from metastatic liver lesion. The main goal of treatment of patients with liver metastases is the achievement of resectability of metastases. “Conversion therapy" in combination with surgery clearly improves the prognosis of patients with liver metastases, making the long-term outcomes comparable to those of initially resectable metastases. The choosing the optimal mode, which would allow to perform radical resection in the maximum number of patients, is still an unsolved problem. Despite the theoretical underpinnings of preoperative therapy in resectable patients (reducing the size of metastases with performing more conservative resections and increasing likelihood of complete tumor resection; exclusion of patients with early extrahepatic disease progression during chemotherapy; relevant choice of postoperative treatment by assessing the chemosensitivity of the tumor and tolerability of treatment by the patient), direct evidence for these arguments are missing.

Full Text

Restricted Access

About the authors

M. I Sekacheva

References

  1. Ferlay J., Shin H.R., Bray F., et al. GLOBOCAN 2008,Version 1.2, Cancer Incidence and Mortality Worldwide.IARC CancerBase No. 10. Available at http://globocan.iarc.fr, accessed November 23, 2011.
  2. Sung J.J., Lau J.Y., Goh K.L., et al. Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol 2005;6:871 -76.
  3. Nordlinger B., Van Cutsem E., Rougier P., et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43(14):2037-45.
  4. Van den Eynde M., Hendlisz A. Treatment of colorectal liver metastases: A review. Rev Recent Clin Trials 2009;4:56-62.
  5. Poston G.J., Figueras J., Giuliante F., et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008;26:4828-33.
  6. Aloia T.A., Adam R., Azoulay D., et al. Outcome following hepatic resection of metastatic renal tumors: The Paul Brousse Hospital experience. HPB (Oxford) 2006;8:100-5.
  7. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, 2009.
  8. Пылев А.Л., Сагайдак И.В., Котельников А.Г. и др. Современные подходы к лечению метастазов колоректального рака в печени // Вестник хирургической гастроэнтерологии 2008. № 4. С. 14-28.
  9. Nordlinger B., Vauthey J.N., Poston G., et al. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 2010;9:212-18.
  10. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83.
  11. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
  12. Fowler W.C., Eisenberg B.L., Hoffman J.P. Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 1992;51(2):122-25.
  13. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
  14. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases down-staged by chemotherapy: A model to predict longterm survival. Ann Surg 2004;240:644-56 and 657-8, discussion.
  15. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520 and 520-2, discussion.
  16. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., et al. irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. irinotecan Study Group. N Engl J Med 2000;343(13):905-14.
  17. Maiello E., Gebbia V., Giuliani F., et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase ii study of the Southern italy Oncology Group. Ann Oncol. 2000 Aug;11(8):1045-51.
  18. Capussotti L., Muratore A., Mulas M.M., et al. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 2006;93:1001-6.
  19. Nuzzo G., Giuliante F., Ardito F., et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007; 1:318-24.
  20. Rivoire M., De Cian F., Meeus P., et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:2283-92.
  21. Falcone A., Ricci S., Brunetti I., et al. Phase iii trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXiRi) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFiRi) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670-76.
  22. Masi G., Loupakis F., Pollina L., et al. Longterm outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXiRi) followed by radical surgery of metastases. Ann Surg 2009;249(3):420-25.
  23. Ychou M., Viret F., Kramar A., et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFiRiNOX): a phase ii study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62(2):195-201.
  24. Arkenau H.T., Arnold D., Cassidy J., et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008;26:5910-17.
  25. Vasile E., Masi G., Fornaro L., et al. A multicenter Phase ii study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer 2009;100:1720-4.
  26. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11(1):38-47.
  27. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. The Oncologist 2007;12:825-39.
  28. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052-64.
  29. Adam R., Wicherts D.A., de Haas R.J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 2008;26:1635-41.
  30. Allen P.J., Kemeny N., Jarnagin W., et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109-15.
  31. Neumann U.P., Thelen A., Röcken C., et al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery 2009;146:52-9.
  32. Vigano L., Capussotti L., Barroso E., et al. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol 2012 Sep; 19(9):2 786-96.
  33. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;3 71(9617): 1007-16.
  34. Sorbye H., Mauer M., Gruenberger T., et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012 Mar;255(3):534-39.
  35. Adam R., Bhangui P., Poston G., et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010;252:774-87.
  36. Oh S.Y., Kim D.Y., Kim Y.B., Suh K.W. Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases. J Surg Res 2012;20( 12): 1842-42.
  37. Ciliberto D., Prati U., Roveda L., et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep 2012;27(6):1849-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media